{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:49:31Z","timestamp":1792090171502,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["857560"],"award-info":[{"award-number":["857560"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.burns.2026.108253","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:40:38Z","timestamp":1791528038000},"page":"108253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-genetic factors play a more important role in lansoprazole metabolism than CYP2C19 pharmacogenetic profiles in European patients with burns"],"prefix":"10.1016","volume":"52","author":[{"given":"Natalie","family":"Mlcuchova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Janosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Zendulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Gregorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Pes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Fiamoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bretislav","family":"Lipovy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Borilova Linhartova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.burns.2026.108253_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/wound.2019.0963","article-title":"A critical update of the assessment and acute management of patients with severe burns","volume":"8","author":"Lang","year":"2019","journal-title":"Adv Wound Care"},{"key":"10.1016\/j.burns.2026.108253_bib2","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1093\/jbcr\/irac012.257","article-title":"703 evaluation of a stress ulcer prophylaxis protocol in an burn intensive care unit","volume":"43","author":"Drabick","year":"2022","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.burns.2026.108253_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.burnso.2026.100462","article-title":"Enteral esomeprazole and intravenous pantoprazole for stress ulcer prophylaxis in critically ill burn patients: an exploratory retrospective study","volume":"15","author":"Takei","year":"2026","journal-title":"Burns Open"},{"key":"10.1016\/j.burns.2026.108253_bib4","unstructured":"Pharmacogene Variation Consortium. CYP2C19, PharmVar n.d. https:\/\/www.pharmvar.org\/gene\/CYP2C19 (accessed August 14, 2026)."},{"key":"10.1016\/j.burns.2026.108253_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-025-00549-6","article-title":"Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6","volume":"11","author":"Krebs","year":"2026","journal-title":"Npj Genom Med"},{"key":"10.1016\/j.burns.2026.108253_bib6","unstructured":"rs12248560 RefSNP Report - dbSNP - NCBI n.d. https:\/\/www.ncbi.nlm.nih.gov\/snp\/rs12248560 (accessed August 14, 2026)."},{"key":"10.1016\/j.burns.2026.108253_bib7","unstructured":"rs4244285 RefSNP Report - dbSNP - NCBI n.d. https:\/\/www.ncbi.nlm.nih.gov\/snp\/rs4244285 (accessed August 14, 2026)."},{"key":"10.1016\/j.burns.2026.108253_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.14735\/amgh2018320","article-title":"Personalized therapy in patients with gastroesophageal reflux disease \u2013 methodology of CYP2C19 gene profile\u2018s determination","volume":"72","author":"Bo\u0159ilov\u00e1 Linhartov\u00e1","year":"2018","journal-title":"Gastroent Hepatol"},{"key":"10.1016\/j.burns.2026.108253_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/cpt.1973","article-title":"PharmVar GeneFocus: CYP2C19","volume":"109","author":"Botton","year":"2021","journal-title":"Clin Pharma Ther"},{"key":"10.1016\/j.burns.2026.108253_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.854280","article-title":"CYP2C19 Gene profiling as a tool for personalized stress ulcer prophylaxis with proton pump inhibitors in critically Ill patients - recommendations proposal","volume":"9","author":"Bo\u0159ilov\u00e1 Linhartov\u00e1","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.burns.2026.108253_bib11","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s11696-019-00682-4","article-title":"Determination of lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone in human plasma for CYP2C19 and CYP3A4 phenotyping","volume":"73","author":"Kostolansk\u00e1","year":"2019","journal-title":"Chem Pap"},{"key":"10.1016\/j.burns.2026.108253_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00228-011-1151-z","article-title":"Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype\u2013phenotype correlation in childhood","volume":"68","author":"Gumus","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.burns.2026.108253_bib13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin Pharma Ther"},{"key":"10.1016\/j.burns.2026.108253_bib14","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/jcm9092890","article-title":"Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review","volume":"9","author":"Klomp","year":"2020","journal-title":"JCM"},{"key":"10.1016\/j.burns.2026.108253_bib15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.114.061093","article-title":"Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine","volume":"43","author":"Shah","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.burns.2026.108253_bib16","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1111\/bcp.15349","article-title":"Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity","volume":"88","author":"Kvitne","year":"2022","journal-title":"Brit J Clin Pharma"},{"key":"10.1016\/j.burns.2026.108253_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 Enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.burns.2026.108253_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/dmd.121.000624","article-title":"CYP2C19 Plays a major role in the hepatic N-oxidation of cotinine","volume":"51","author":"Perez-Paramo","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.burns.2026.108253_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.1993.tb00386.x","article-title":"Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole","volume":"36","author":"Hussein","year":"1993","journal-title":"Brit J Clin Pharma"},{"key":"10.1016\/j.burns.2026.108253_bib20","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2165\/00003088-200544110-00005","article-title":"The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics","volume":"44","author":"Ishizawa","year":"2005","journal-title":"Clin Pharmacokinet"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417926004055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417926004055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:58:48Z","timestamp":1792087128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417926004055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0305417926004055"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2026.108253","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-genetic factors play a more important role in lansoprazole metabolism than CYP2C19 pharmacogenetic profiles in European patients with burns","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2026.108253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108253"}}